Dalazatide

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameDalazatide
Drug Alias NameDebio-0824ShK-186
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionVoltage-gated potassium channel subunit Kv1.3 blockersT lymphocytes modulators
TargetsVoltage-gated potassium channel subunit Kv1.3
Therapy Area/IndicationsPlaque psoriasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDebiopharm Group
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKineta Inc
Active IndicationsN/A
Inactive IndicationsPlaque psoriasis

Other Information

ATC CodeN/A
Related LinksN/A